Cited by 350Nanoparticle-Based Drug DeliveryNanoplatforms for cancer theranosticsRNA Interference and Gene Delivery

Ligand-installed nanocarriers toward precision therapy

Mi, Peng, Cabral, Horacio, Kataoka, Kazunori·2020·Advanced Materials

Abstract

Development of drug-delivery systems that selectively target neoplastic cells has been a major goal of nanomedicine. One major strategy for achieving this milestone is to install ligands on the surface of nanocarriers to enhance delivery to target tissues, as well as to enhance internalization of nanocarriers by target cells, which improves accuracy, efficacy, and ultimately enhances patient outcomes. Herein, recent advances regarding the development of ligand-installed nanocarriers are introduced and the effect of their design on biological performance is discussed. Besides academic achievements, progress on ligand-installed nanocarriers in clinical trials is presented, along with the challenges faced by these formulations. Lastly, the future perspectives of ligand-installed nanocarriers are discussed, with particular emphasis on their potential for emerging precision therapies.

Integrity signals

Registry

Crossref · 10.1002/adma.201902604

Cites

316 of 316 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Mi, P., Cabral, H., & Kataoka, K.
Affiliations
  • Sichuan University (CN)
  • The University of Tokyo (JP)
  • Innovation Center of NanoMedicine (JP)
Corresponding author
Kataoka, Kazunori
Venue
Advanced Materials
Publisher
Wiley
Published
2019-07-28
Volume
32
Issue
13
Pages
e1902604-e1902604
ISSN
  • 0935-9648 (ISSN-L)
  • 1521-4095
OpenAlex
W2964415910
Cited by
350
References
316
Citations by year
2026: 22 · 2025: 40 · 2024: 56 · 2023: 48 · 2022: 52 · 2021: 64 · 2020: 55 · 2019: 13
FWCI
2.93
Type
journal article
Language
en
Open access
closed
Locations
  • Advanced Materials (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Basic Research Program of China (2017YFA0207900)
  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
targeted drug delivery, tumor targeting, nanomedicine, ligand-receptor interactions, precision therapy, nanocarrier design
MeSH terms
Animals, Antineoplastic Agents, Drug Carriers, Humans, Ligands, Neoplasms, Drug Delivery Systems, Nanostructures, Nanomedicine, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review